The US Food and Drug Administration has approved a new long-acting HIV prevention injection that could make pre-exposure prophylaxis easier for many people at risk. The drug, lenacapavir, is designed to be given once every four weeks, offering a less frequent option than daily pills for preventing HIV infection.

The approval covers adults and adolescents who are considered at risk of acquiring HIV. Public health experts have long argued that more convenient dosing can improve adherence, which is a major challenge in prevention programs. A monthly injectable option may help close gaps for people who struggle to take medication every day.

The decision adds another tool to the fight against HIV, a virus that still affects millions worldwide. While access, affordability, and rollout will shape its impact, the approval marks a significant step for prevention medicine in the United States.

Health advocates are likely to view the move as a welcome development, especially if it expands choices for communities facing higher HIV risk. The coming months will show how quickly providers and patients can adopt the new injection in real-world care.